206. 脆弱Ｘ症候群 Fragile X syndrome Clinical trials / Disease details
臨床試験数 : 108 / 薬物数 : 91 - (DrugBank : 36) / 標的遺伝子数 : 52 - 標的パスウェイ数 : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01894958 (ClinicalTrials.gov) | January 2014 | 3/7/2013 | A Safety Study of NNZ-2566 in Patients With Fragile X Syndrome | A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study of NNZ-2566 in Fragile X Syndrome | Fragile X Syndrome | Drug: NNZ-2566;Drug: Placebo | Neuren Pharmaceuticals Limited | NULL | Completed | 12 Years | 45 Years | Male | 72 | Phase 2 | United States |